Fig. 1
Accumulation of three types of theranostic liposomes (indicated by yellow, purple, and blue) (with various formulations or components, imaging agents, fluorescence dye, radiopharmaceuticals and therapeutic agents) at the tumor site and their evaluation through pre-clinical and clinical stages. Real-time and quantitative feedback of liposomal drug delivery acquired noninvasively through a specific imaging modality can be further exploited to optimize and personalize therapy after the selection of an optimum liposomal therapeutic for an individual. The blue liposome successfully progressed to clinical usage, indicating its potential as an effective treatment option